Missing Information
  • A System Error Has Occured:0177 - Failed to Load All Sections.
Company:  FOAMIX PHARMACEUTICALS LT ... (FOMX)
Form Type:  8-K
Filing Date:  1/14/2020 
CIK:  0001606645 
Address:  2 HOLZMAN ST.
WEIZMANN SCIENCE PARK
 
City, State, Zip:  REHOVOT,  76704 
Telephone:  97289316233 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.70  
Change: 
0.02 (0.43%)  
Trade Time: 
Jan 17  
Market Cap: 
$289.44M
Trade FOMX now with 

© 2020  
Description of Business
We are a late clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary, innovative and differentiated topical drug candidates for dermatological therapy. Our lead product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and our second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are novel topical foam formulations of the antibiotic minocycline and were developed using our Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline, an active pharmaceutical ingredient, or API, that is currently available only in oral form despite its prevalent use in dermatology. We announced positive top-line results from both of our Phase III clinical trials for each of FMX101 and FMX103 in the second half of 2018.